Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Alexion Pharmaceuticals (NasdaqNM:ALXN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
Aug 21Price hit new 52-week low ($15.25)
Location
352 Knotter Drive
Cheshire, CT 06410
Phone: (203) 272-2596
Fax: (203) 271-8198
Email: investor.relations@alxn.com
Employees (last reported count): 113
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 60%
·Over the last 6 months:
 · one insider buy; 9,000  shares
·Institutional: 81% (204% of float)
(178 institutions)
·Net Inst. Selling: 2.93M shares (+25.00%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Alexion Pharmaceuticals develops products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The Company's lead product candidates are genetically altered antibodies that target specific diseases that arise when the human immune system induces undesired inflammation in the human body. The Company's lead product candidates are designed to block components of the human immune system that cause inflammation while allowing beneficial components of the immune system to remain functional. The Company's two lead genetically altered antibody product candidates are designed to block the inflammatory effects of the components of the immune system known as "complement," and are 5G1.1-SC for the treatment of acute inflammation caused by the trauma of heart and lung bypass procedures during open heart surgery and 5G1.1 for the chronic treatment of rheumatoid arthritis, membranous nephritis and psoriasis, dermatomyositis and bullous pemphigoid.
More from Market Guide: Expanded Business Description

Financial Summary
Alexion Pharmaceuticals is a biopharmaceutical company engaged in the development of products for the treatment of cardiovascular, autoimmune and neurologic diseases. For the nine months ended 4/30/01, revenues fell 51% to $8.5 million. Net loss before acctg. chg. totaled $40.4 million, up from $15.1 million. Results reflect decreased contract revenues due to lower related expense reimbursements from Proctor and Gamble. Higher loss reflects a $21 million in-process R&D charge.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

John Fried, Ph.D., 70
Chairman
--  
Leonard Bell, M.D., 42
Pres, CEO, Sec., Treasurer, Director
$436K
David Keiser, 49
Exec. VP, COO
260K
Stephen Squinto, Ph.D., 44
Exec. VP and Head of Research
223K
Barry Luke, 42
VP-Fin., VP-Admin., Assistant Sec.
--  
Dollar amounts are as of 31-July-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ALXNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 21-Aug-2001
$15.25 
Recent Price$18.85 
52-Week High
on 22-Sep-2000
$118.625
Beta1.45 
Daily Volume (3-month avg)213.1K
Daily Volume (10-day avg)194.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-81.4%
52-Week Change
relative to S&P500
-75.0%
Share-Related Items
Market Capitalization$341.1M
Shares Outstanding18.1M
Float7.20M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$14.78 
Earnings (ttm)-$2.87 
Earnings (mrq)-$0.36 
Sales (ttm)$0.75 
Cash (mrq)$20.10 
Valuation Ratios
Price/Book (mrq)1.27 
Price/EarningsN/A 
Price/Sales (ttm)25.01 
Income Statements
Sales (ttm)$12.5M
EBITDA (ttm)-$52.4M
Income available to common (ttm)-$45.5M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsJuly 31
Most recent quarter30-Apr-2001
Management Effectiveness
Return on Assets (ttm)-16.05%
Return on Equity (ttm)-30.12%
Financial Strength
Current Ratio (mrq)52.92 
Debt/Equity (mrq)0.46 
Total Cash (mrq)$363.7M
Short Interest
As of 8-Aug-2001
Shares Short794.0K
Percent of Float11.0%
Shares Short
(Prior Month)
787.0K
Short Ratio5.29 
Daily Volume150.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-Apr-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.